On March 22, 2022, all study sites have met the criteria to provide treatment in the cross-over extension study for MAPS-sponsored Phase 3 trials of MDMA-assisted therapy for posttraumatic stress disorder (PTSD).
All the subjects who received the placebo, plus therapy, in the double-blind portion of our first Phase 3 study of MDMA-assisted therapy for PTSD have the opportunity to volunteer to participate in the study protocol again for free to receive therapy plus MDMA.
